Sporadic PD may include impaired mitochondrial quality control, reduced mitophagy flux, and dopaminergic vulnerability overlapping with PINK1/Parkin biology. The most defensible program is biomarker-led and should test whether candidate therapies restore mitochondrial flux and neuronal resilience rather than assuming canonical familial-PD mitophagy is dominant in all sporadic cases.
No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for PINK1; yet. Search RCSB →
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for PINK1; PARK2; MFN2; OPTN.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.